FEV1Q as a race-neutral assessment of lung function in Nepal, Peru and Uganda

Eur Respir J. 2026 May 7;67(5):2501830. doi: 10.1183/13993003.01830-2025. Print 2026 May.

Abstract

Background: Forced expiratory volume in 1 s quotient (FEV1Q) is a race-neutral expression of lung function. The validity and utility of FEV1Q across Global South populations has not been previously explored.

Methods: We conducted a post-hoc analysis of data from the Global Excellence in COPD Outcomes-1 and -2 (GECo1 and GECo2) studies in which a random age- and sex-stratified population of 10 709 people were recruited in Nepal, Peru and Uganda. The FEV1 first percentile (used to derive FEV1Q) was estimated in those with COPD by site and sex. We examined associations between FEV1Q, risk factors and respiratory morbidity. We estimated the rate of decline in FEV1Q. We evaluated the discriminative accuracy of FEV1Q in diagnosing COPD.

Results: The first percentiles of FEV1 in those with COPD, at 0.43 L in women and 0.52 L in men, were similar to those previously used to calculate FEV1Q. Lower FEV1Q was associated with older age, lower socioeconomic status, shorter height and greater smoking pack-years. We estimated that decline in FEV1Q with age was 0.65 (95% CI 0.64-0.67) units per 10 years, and more rapid in those continuing to smoke at 0.82 (95% CI 0.77-0.87) units per 10 years. FEV1Q was lower in those with prior respiratory hospitalisations and impairment in daily activities due to respiratory disease, and associated with future hospitalisation risk in the GECo2 study. Pre-bronchodilator FEV1Q had reasonable diagnostic accuracy for COPD (area under the curve (AUC) 0.87, 95% CI 0.85-0.88), similar to pre-bronchodilator FEV1 % predicted (AUC 0.88, 95% CI 0.87-0.90).

Conclusion: Our data support the validity and utility of FEV1Q as a race-neutral approach to lung function assessment in diverse settings, including the Global South where the burden of lung disease is greatest.

MeSH terms

  • Adult
  • Aged
  • Female
  • Forced Expiratory Volume
  • Humans
  • Lung* / physiopathology
  • Male
  • Middle Aged
  • Nepal / epidemiology
  • Peru / epidemiology
  • Pulmonary Disease, Chronic Obstructive* / diagnosis
  • Pulmonary Disease, Chronic Obstructive* / physiopathology
  • Respiratory Function Tests
  • Risk Factors
  • Smoking
  • Uganda / epidemiology